Mycophenolate mofetil for the management of autoimmune bullous diseases.

Abstract

Immunosuppressive agents such as azathioprine, cyclophosphamide, and mycophenolate mofetil (MMF) are now widely used in the treatment of autoimmune bullous diseases. This article reviews the use of MMF for the treatment of several bullous conditions, and assesses the evidence gathered from clinical trials and case series. According to numerous case series, MMF could be of value in treating refractory disease. The few randomized clinical trials conducted to date of patients with pemphigus and bullous pemphigoid report a similar efficacy for MMF to other immunosuppressants.

• Authors: Marina Eskin-Schwartz, Michael David, Daniel Mimouni
• Journal: Immunology and allergy clinics of North America (Immunol Allergy Clin North Am) Vol. 32 Issue 2 Pg. 309-15, vii (May 2012) ISSN: 1557-8607 [Electronic] United States
• PMID: 22560143 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2012 Elsevier Inc. All rights reserved.

Chemical References

• Anti-Inflammatory Agents
• Mycophenolic Acid

Topics

• Animals
• Anti-Inflammatory Agents (therapeutic use)
• Autoimmune Diseases (drug therapy, immunology)
• Evidence-Based Medicine
• Humans
• Immunosuppression Therapy
• Mycophenolic Acid (analogs & derivatives, chemistry, therapeutic use)
• Randomized Controlled Trials as Topic
• Skin Diseases, Vesiculobullous (drug therapy, immunology)